BioPharma Credit PLC - life sciences debt investment trust - Notes Monday's announcement from Ipsen regarding its agreement to acquire Epizyme Inc. BioPharma has a USD110 million investment in a senior secured loan in Epizyme, which it says would be prepaid upon closing of the acquisition. "The loan was made in four different tranches with each tranche having a different prepayment economics. Depending on the actual timing of the prepayment, the company would be expected to receive between USD3 million to USD7 million in prepayment and make-whole fees," company explains.
Current stock price: USD0.95
12-month change: down 2.5%
By Elizabeth Winter; elizabethwinter@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Biopharma Cred. (BPCR)